Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients
- 1 December 2002
- journal article
- Published by Elsevier BV in American Journal of Kidney Diseases
- Vol. 40 (6), 1283-1288
- https://doi.org/10.1053/ajkd.2002.36899
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- New Vitamin D AnalogsSeminars in Dialysis, 2001
- New analogs of vitamin D3Kidney International, 1999
- A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor contentAmerican Journal of Kidney Diseases, 1997
- Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidismAmerican Journal of Kidney Diseases, 1996
- Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patientsPediatric Nephrology, 1996
- Pathogenesis of secondary hyperparathyroidismNephrology Dialysis Transplantation, 1996
- A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemiaAmerican Journal of Kidney Diseases, 1995
- Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patientsKidney International, 1992
- Intravenous Calcitriol in the Treatment of Refractory Osteitis Fibrosa of Chronic Renal FailureNew England Journal of Medicine, 1989
- Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.JCI Insight, 1984